A suspected delayed hemolytic transfusion reaction mediated by anti-Joa

Publications

Share / Export Citation / Email / Print / Text size:

Immunohematology

American National Red Cross

Subject: Medical Laboratory Technology

GET ALERTS SUBSCRIBE

ISSN: 0894-203X
eISSN: 1930-3955

DESCRIPTION

10
Reader(s)
21
Visit(s)
0
Comment(s)
0
Share(s)

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue / page

Archive
Volume 37 (2021)
Volume 36 (2020)
Volume 35 (2019)
Volume 34 (2018)
Volume 33 (2017)
Volume 32 (2016)
Volume 31 (2015)
Volume 30 (2014)
Volume 29 (2013)
Volume 28 (2012)
Volume 27 (2011)
Volume 26 (2010)
Volume 25 (2009)
Volume 24 (2008)
Volume 23 (2007)
Volume 22 (2006)
Volume 21 (2005)
Volume 20 (2004)
Volume 19 (2003)
Volume 18 (2002)
Volume 17 (2001)
Volume 16 (2000)
Volume 15 (1999)
Volume 14 (1998)
Volume 13 (1997)
Volume 12 (1996)
Volume 11 (1995)
Volume 10 (1994)
Volume 9 (1993)
Volume 8 (1992)
Volume 7 (1991)
Volume 6 (1990)
Volume 5 (1989)
Volume 4 (1988)
Volume 3 (1987)
Related articles

VOLUME 33 , ISSUE 2 (June 2017) > List of articles

A suspected delayed hemolytic transfusion reaction mediated by anti-Joa

Ryan P. Jajosky * / Wendy C. Lumm / Scott C. Wise / Roni J. Bollag / James F. Shikle

Keywords :  Joa, delayed hemolytic transfusion reaction (DHTR), Dombrock blood group system, high-prevalence antigen

Citation Information : Immunohematology. Volume 33, Issue 2, Pages 73-75, DOI: https://doi.org/10.21307/immunohematology-2019-011

License : (Transfer of Copyright)

Published Online: 09-October-2019

ARTICLE

ABSTRACT

A 32-year-old African-American woman with a history of sickle cell disease presented for surgical evaluation of left total hip arthroplasty due to avascular necrosis of the femoral head. In anticipation of a complex orthopedic procedure, pre-surgical blood work was ordered. The patient’s Fenwal blood sample typed as group O, D+. Although the patient had a history of anti-Fya, the antibody identification was inconclusive, so the workup was sent to a reference laboratory. The patient was last transfused with red blood cells (RBCs) 2 years earlier, but had no history of transfusion reactions. Due to surgery, the patient’s hemoglobin (Hb) decreased from 10.2 g/dL (preoperative) to 8.6 g/dL (postoperative). One unit of weakly crossmatchincompatible Fy(a–), C–, E–, K–, and sickle cell hemoglobin S (HbS)-negative RBCs was transfused without incident, and the patient was discharged. Several days later, the reference lab reported two new specificities, anti-Joa and anti-Jkb. Fortunately, the transfused RBC unit was Jk(b–). Therefore, the crossmatch incompatibility was attributed to anti-Joa, which targets a highprevalence antigen found in 100 percent of most populations. Two weeks after discharge, the patient returned in sickle vasoocclusive pain crisis. The patient was clinically stable, but her Hb was 6.7 g/dL.  One unit of Fy(a–), Jk(b–), C–, E–, K–, HbS– RBCs, which was weakly crossmatch-incompatible, was transfused. The following day, her Hb was unchanged, lactic acid dehydrogenase increased from 951 to 2464 U/L, potassium increased from 3.7 to 4.6 mEq/L, creatinine increased from 0.60 to 0.98 mg/dL, and the patient developed a 38.4°C fever. These findings are consistent with a delayed hemolytic transfusion reaction (DHTR), mediated by anti-Joa, occurring 2 weeks after the first RBC transfusion. Further care could not be provided because the patient left the hospital against medical advice. The purpose of this case study is to report findings consistent with a DHTR attributed to antiJoa, an antibody with relatively unknown clinical significance.

You don't have 'Full Text' access of this article.

Purchase Article Subscribe Journal Share